SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kurt A. Jellinger, Neuropathobiology of non-motor symptoms in Parkinson disease, Journal of Neural Transmission, 2015, 122, 10, 1429

    CrossRef

  2. 2
    Lauren Walker, Kirsty E. McAleese, Alan J. Thomas, Mary Johnson, Carmen Martin-Ruiz, Craig Parker, Sean J. Colloby, Kurt Jellinger, Johannes Attems, Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes, Acta Neuropathologica, 2015, 129, 5, 729

    CrossRef

  3. 3
    V. Kotagal, R. L. Albin, M. L. T. M. Muller, R. A. Koeppe, S. Studenski, K. A. Frey, N. I. Bohnen, Advanced Age, Cardiovascular Risk Burden, and Timed Up and Go Test Performance in Parkinson Disease, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2014, 69, 12, 1569

    CrossRef

  4. 4
    David A. Bennett, Lei Yu, Philip L. De Jager, Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease, Biochemical Pharmacology, 2014, 88, 4, 617

    CrossRef

  5. 5
    Kurt A Jellinger, The pathomechanisms underlying Parkinson's disease, Expert Review of Neurotherapeutics, 2014, 14, 2, 199

    CrossRef

  6. 6
    K. Del Tredici, H. Braak, Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia, Journal of Neurology, Neurosurgery & Psychiatry, 2013, 84, 7, 774

    CrossRef

  7. 7
    Glenda Halliday, Heather McCann, Claire Shepherd, Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?, Expert Review of Neurotherapeutics, 2012, 12, 6, 673

    CrossRef

  8. 8
    Kurt A Jellinger, Neurobiology of cognitive impairment in Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 12, 1451

    CrossRef

  9. 9
    Kurt A. Jellinger, Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts, Movement Disorders, 2012, 27, 1
  10. 10
    J. F. Burke, R. L. Albin, R. A. Koeppe, B. Giordani, M. R. Kilbourn, S. Gilman, K. A. Frey, Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography, Brain, 2011, 134, 6, 1647

    CrossRef

  11. 11
    Naroa Ibarretxe-Bilbao, Carme Junque, Maria J. Marti, Eduardo Tolosa, Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease, Journal of the Neurological Sciences, 2011, 310, 1-2, 70

    CrossRef

  12. 12
    James B. Leverenz, G. Stennis Watson, Jane Shofer, Cyrus P. Zabetian, Jing Zhang, Thomas J. Montine, Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease, Parkinsonism & Related Disorders, 2011, 17, 1, 61

    CrossRef

  13. 13
    Vincenzo Solfrizzi, Francesco Panza, Vincenza Frisardi, Davide Seripa, Giancarlo Logroscino, Bruno P Imbimbo, Alberto Pilotto, Diet and Alzheimer’s disease risk factors or prevention: the current evidence, Expert Review of Neurotherapeutics, 2011, 11, 5, 677

    CrossRef

  14. 14
    John C.S. Breitner, Further Evidence for Vascular Mediation of Alzheimer's Dementia Pathogenesis?, Biological Psychiatry, 2011, 70, 2, 113

    CrossRef

  15. 15
    Kurt A. Jellinger, Interaction between α-synuclein and tau in Parkinson's disease, Experimental Neurology, 2011, 227, 1, 13

    CrossRef

  16. 16
    Glenda Halliday, Andrew Lees, Matthew Stern, Milestones in Parkinson's disease—Clinical and pathologic features, Movement Disorders, 2011, 26, 6
  17. 17
    Kurt A. Jellinger, Synuclein deposition and non-motor symptoms in Parkinson disease, Journal of the Neurological Sciences, 2011, 310, 1-2, 107

    CrossRef

  18. 18
    Current awareness in geriatric psychiatry, International Journal of Geriatric Psychiatry, 2010, 25, 11